Zheng Min, Li Shaoxing, Deng Jie, Huang Chaolin, Zhang Hua
Department of Gynecology and Obstetrics, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, People's Republic of China.
Department of Rehabilitation Medicine, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, People's Republic of China.
Int J Gen Med. 2025 Jan 8;18:103-111. doi: 10.2147/IJGM.S499524. eCollection 2025.
This study aimed to investigate the clinical significance of heat shock protein 60 (HSP60) expression in ovarian cancer and evaluate its correlation with patient survival outcomes.
A total of 260 ovarian cancer patients diagnosed between 2017 and 2019 were enrolled. Immunohistochemistry was performed to assess HSP60 expression in tumor tissues. Patients were categorized into high- or low-HSP60 expression groups based on immunohistochemical staining intensity. The correlation between HSP60 expression status and the clinicopathological features of ovarian cancer patients was analyzed. Kaplan-Meier survival curves and Cox regression models were utilized to evaluate overall survival and disease-free survival.
HSP60 expression was significantly higher in ovarian cancer tissues compared to normal ovarian tissues. High HSP60 expression was associated with larger tumor size, advanced FIGO stage, and increased lymph node metastasis. Patients with high HSP60 expression exhibited significantly shorter overall survival and disease-free survival than those with low expression. Multivariate Cox analysis identified HSP60 as an independent prognostic factor for both overall survival and disease-free survival.
High HSP60 expression is associated with poor prognosis and aggressive tumor characteristics in ovarian cancer. HSP60 may serve as a valuable biomarker for prognosis and a potential therapeutic target. Further randomized clinical trials are warranted to explore its role in ovarian cancer progression and treatment strategies.
本研究旨在探讨热休克蛋白60（HSP60）在卵巢癌中的表达的临床意义，并评估其与患者生存结局的相关性。
纳入2017年至2019年间确诊的260例卵巢癌患者。采用免疫组织化学法评估肿瘤组织中HSP60的表达。根据免疫组织化学染色强度将患者分为HSP60高表达组或低表达组。分析HSP60表达状态与卵巢癌患者临床病理特征之间的相关性。采用Kaplan-Meier生存曲线和Cox回归模型评估总生存期和无病生存期。
与正常卵巢组织相比，卵巢癌组织中HSP60的表达显著更高。HSP60高表达与肿瘤体积较大、国际妇产科联盟（FIGO）分期较晚以及淋巴结转移增加有关。HSP60高表达的患者的总生存期和无病生存期明显短于低表达患者。多变量Cox分析确定HSP60是总生存期和无病生存期的独立预后因素。
HSP60高表达与卵巢癌预后不良和肿瘤侵袭性特征相关。HSP60可能作为一种有价值的预后生物标志物和潜在的治疗靶点。有必要进一步开展随机临床试验，以探讨其在卵巢癌进展和治疗策略中的作用。
